文献速递肝病

肥胖与体重增加与非酒精性脂肪性肝病患者肝纤维化进展相关

Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-09-11

该前瞻性队列研究纳入韩国40,700名接受定期健康筛查的非酒精性脂肪性肝病(NAFLD)成人,中位随访6.0年,以天冬氨酸氨基转移酶与血小板比率指数(APRI)评估纤维化进展。结果显示体重增加和基线BMI升高均与APRI进展风险独立相关;作者认为保持正常健康体重和防止体重增加可能有助于减少NAFLD患者的纤维化进展。

要点

  • 中位随访6.0年,5454名基线低APRI者进展为中或高APRI。
  • 与体重稳定组(第三五分位)相比,体重增加组APRI进展风险升高。
  • 基线BMI≥30 kg/m2者APRI进展风险约为BMI 18.5-22.9 kg/m2者的2.09倍。

核心结论

  • 在40,700名NAFLD成人的前瞻性队列中,肥胖和体重增加与基于APRI的纤维化进展风险升高独立相关。
  • 作者认为保持正常健康体重和防止体重增加可能有助于减少NAFLD个体的纤维化进展。

研究设计与样本

  • 前瞻性队列研究,纳入韩国40,700名接受定期健康筛查的NAFLD成人,中位随访6.0年。
  • 体重变化定义为基线体重与后续随访体重之差。
  • 采用APRI评估从低概率向中或高概率进展性纤维化的进展。

主要发现

  • 随访共275,421.5人年,5454名基线低APRI受试者进展为中或高APRI。
  • 以体重稳定组(第三五分位)为参照,第一、第二、第四、第五五分位体重变化的APRI进展多变量校正HR分别为0.68(95%CI 0.62-0.74)、0.86(95%CI 0.78-0.94)、1.17(95%CI 1.07-1.28)、1.71(95%CI 1.58-1.85)。
  • 以BMI 18.5-22.9 kg/m2为参照,BMI 23-24.9、25-29.9、≥30 kg/m2者的APRI进展多变量校正HR分别为1.13(95%CI 1.02-1.26)、1.41(95%CI 1.28-1.55)、2.09(95%CI 1.86-2.36)。

临床怎么用

  • 作者认为保持正常健康体重和防止体重增加可能有助于减少NAFLD个体的纤维化进展。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The effects of weight change on the progression of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) in the general population are unclear. We evaluated the association of weight change and baseline body mass index (BMI) with fibrosis progression, determined by non-invasive measurement of a marker, in young and middle-aged adults with NAFLD. METHODS: We performed a prospective cohort study of 40,700 adults with NAFLD in Korea who received regular health screening examinations and were followed for a median 6.0 years. Weight change was defined as the difference between weights measured at baseline and at a subsequent follow-up visit. The progression from a low to an intermediate or high probability of advanced fibrosis was assessed using the aspartate aminotransferase to platelet ratio index (APRI). RESULTS: During 275,421.5 person-years of follow-up, 5454 subjects with a low APRI progressed to an intermediate or high APRI. Multivariable-adjusted hazard ratios for APRI progression, determined by comparing the first and second weight change quintiles (the weight-loss group) and the fourth and fifth quintiles (weight-gain group) with the third quintile (weight-stable group, reference), were 0.68 (95% CI, 0.62-0.74), 0.86 (95% CI, 0.78-0.94), 1.17 (95% CI, 1.07-1.28), and 1.71 (95% CI, 1.58-1.85), respectively. The multivariable-adjusted hazard ratios for APRI progression were determined by comparing subjects with BMIs of 23-24.9, 25-29.9, and ≥30 with subjects with BMIs of 18.5-22.9 kg/m2 (reference); these ratios were 1.13 (95% CI, 1.02-1.26), 1.41 (95% CI, 1.28-1.55), and 2.09 (95% CI, 1.86-2.36), respectively. CONCLUSIONS: In a prospective cohort study of 40,700 adults with NAFLD, we found obesity and weight gain to be independently associated with increased risk of fibrosis progression, based on APRI. Maintaining a normal healthy weight and preventing weight gain may help reduce fibrosis progression in individuals with NAFLD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim Y, Chang Y, Cho YK, et al. Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2018. PMID: 30012432. doi:10.1016/j.cgh.2018.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。